Role of esmolol in non-healing chronic wounds
DOI:
https://doi.org/10.18203/2349-2902.isj20262451Keywords:
Diabetic foot ulcer, Esmolol hydrochloride, Wound healing, Topical therapy, Chronic ulcersAbstract
Background: Diabetic foot ulcers (DFUs) exhibit delayed healing due to persistent inflammation, oxidative stress, microvascular dysfunction, and impaired cellular responses. Topical esmolol hydrochloride has demonstrated wound‑healing potential through inhibition of aldose reductase, reduction of advanced glycation end products, and promotion of epithelial and endothelial migration.
Methods: This observational cohort study included 30 patients with chronic, non‑infected foot or lower‑leg ulcers of more than three weeks’ duration, including diabetic (Wagner class 1A/1B) and non‑diabetic traumatic wounds. Patients received topical esmolol hydrochloride 14% once daily in addition to standard wound care. Wounds were assessed weekly for nine weeks using the Bates–Jensen wound assessment tool (BWAT). Complete healing was defined as full epithelialization without discharge.
Results: Mean BWAT score improved from 28 at baseline to 3 at week 9, representing an 89.3% reduction. Complete healing within 9 weeks was achieved in 24 patients (80%). Healing was significantly higher in non‑anemic patients compared with anemic patients (p<0.05). Patients with normal serum albumin showed better outcomes, while glycemic control showed a positive but non‑significant association.
Conclusions: Topical esmolol hydrochloride appears to be a safe and effective adjunct to standard wound care for diabetic and traumatic foot ulcers. Correction of systemic factors such as anemia and malnutrition further enhances outcomes. Larger randomized studies are required to confirm efficacy.
References
Burgess JL, Wyant WA, AbdoAbujamra B, Kirsner RS, Jozic I. Diabetic wound-healing science. Medicina (Kaunas) 2021;57(10):1072.
Davis FM, Kimball A, Boniakowski A, Gallagher K. Dysfunctional wound healing in diabetic foot ulcers: new crossroads. Curr Diab Rep 2018;18(1):2.
Boykin JV. Wound nitric oxide bioactivity: a promising diagnostic indicator for diabetic foot ulcer management. J Wound Ostomy Continence Nurs. 2010;37(1):25-32.
Reynolds RD, Gorczynski RJ, Quon CY. Pharmacology and pharmacokinetics of esmolol. J Clin Pharmacol. 1986;26(1):A3-14.
Kulkarni SA, Deshpande SK, Rastogi A. Novel topical esmolol hydrochloride improves wound healing in diabetes by inhibiting aldose reductase, generation of advanced glycation end products, and facilitating migration of fibroblasts. Front Endocrinol (Lausanne). 2022;13:926129.
Rastogi A, Kulkarni SA, Deshpande SK, Driver V, Barman H, Bal A, et al. Novel topical esmolol hydrochloride (Galnobax) for diabetic foot wound: phase 1/2 randomized double-blind vehicle-controlled study. Adv Wound Care (New Rochelle). 2023;12(8):429-39.
Rastogi A, Kulkarni SA, Agarwal S, Akhtar M, Arsule S, Bhamre S, et al. Topical esmolol hydrochloride as a novel treatment modality for diabetic foot ulcers: A phase 3 randomized clinical trial. JAMA Netw Open. 2023;6(5):e2311509.
Rastogi A, Singh R, Adhikari U, Kulkarni SA, Deshpande SK. Effect of patient and wound characteristics on diabetic foot ulcer healing in phase 3 study of novel topical esmolol hydrochloride. Int J Diabetes Dev Ctries. 2025;45(1):69-74.
Guo S, DiPietro LA. Factors affecting wound healing. J Dent Res. 2010;89(3):219-29.
Stechmiller JK. Understanding the role of nutrition and wound healing. Nutr Clin Pract. 2010;25(1):61-8.
Falanga V. Wound healing and its impairment in the diabetic foot. Lancet. 2005;366(9498):1736-43.
Armstrong DG, Boulton AJM, Bus SA. Diabetic foot ulcers and their recurrence. N Engl J Med. 2017;376:2367-75.
Brem H, Tomic-Canic M. Cellular and molecular basis of wound healing in diabetes. J Clin Invest. 2007;117(5):1219-22.
Downloads
Published
How to Cite
Issue
Section
